Skip to main content
. 2014 May 20;2014:702701. doi: 10.1155/2014/702701

Table 2.

EULAR responses at next reevaluation after first RA flare.

EULAR response
No Moderate Good P
RTX
 Group A 4 (16%) 5 (20%) 7 (28%) 0.038
 Group B 6 (24%) 2 (10%) 1 (4%)
IFX
 Group A 2 (10%) 5 (25%) 2 (10%) 0.002
 Group B 10 (50%) 1 (5%) 0
ETN
 Group A 3 (16.67%) 5 (27.78%) 7 (38.89%) 0.023
 Group B 3 (16.67%) 0 0
ADL
 Group A 2 (22.22%) 1 (11.11%) 5 (55.56%) 0.194
 Group B 1 (11.11%) 0 0

Differences between EULAR responses in group A and group B were tested using Kruskal-Wallis test, for each biologic agent.

RTX: rituximab; IFX: infliximab; ETN: etanercept; ADL: adalimumab.

Group A: detectable drug level; Group B: undetectable drug level.